No abstract available
Publication types
-
Clinical Trial, Phase I
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies / administration & dosage
-
Antibodies / adverse effects
-
Antibodies / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Chemical and Drug Induced Liver Injury / etiology*
-
Dose-Response Relationship, Drug
-
Early Termination of Clinical Trials
-
Female
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / adverse effects
-
Immunoconjugates / therapeutic use*
-
Lectins, C-Type / antagonists & inhibitors*
-
Lectins, C-Type / immunology
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics
-
Male
-
Middle Aged
-
Mutation
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / immunology
-
Neoplasms, Second Primary / drug therapy
-
Neoplasms, Second Primary / genetics
-
Receptors, Mitogen / antagonists & inhibitors*
-
Receptors, Mitogen / immunology
-
Young Adult
Substances
-
Antibodies
-
Antineoplastic Agents
-
CLEC12A protein, human
-
DCLL9718S
-
Immunoconjugates
-
Lectins, C-Type
-
Neoplasm Proteins
-
Receptors, Mitogen
Associated data
-
ClinicalTrials.gov/NCT03298516